Zaviralec kinaze tarče rapamicina pri sesalcih (Slovenian Wikipedia)

Analysis of information sources in references of the Wikipedia article "Zaviralec kinaze tarče rapamicina pri sesalcih" in Slovenian language version.

refsWebsite

Global rank Slovenian rank

28nih.gov

4^th place

8^th place

20doi.org

2^nd place

5^th place

5semanticscholar.org

11^th place

51^st place

5web.archive.org

1^st place

2^nd place

5europa.eu

68^th place

28^th place

2fda.gov

447^th place

409^th place

1termania.net

low place

34^th place

1cancer.gov

1,684^th place

381^st place

cancer.gov

»FDA approval for Everolimus«. National Cancer Institute. 21. april 2009. Arhivirano iz prvotnega spletišča dne 6. aprila 2015. Pridobljeno 20. septembra 2012.

doi.org

Pópulo H, Lopes JM, Soares P (2012). »The mTOR signalling pathway in human cancer«. International Journal of Molecular Sciences. 13 (2): 1886–1918. doi:10.3390/ijms13021886. PMC 3291999. PMID 22408430.
Strimpakos AS, Karapanagiotou EM, Saif MW, Syrigos KN (april 2009). »The role of mTOR in the management of solid tumors: an overview«. Cancer Treatment Reviews. 35 (2): 148–159. doi:10.1016/j.ctrv.2008.09.006. PMID 19013721.{{navedi časopis}}: Vzdrževanje CS1: samodejni prevod datuma (povezava)
Yuan R, Kay A, Berg WJ, Lebwohl D (Oktober 2009). »Targeting tumorigenesis: development and use of mTOR inhibitors in cancer therapy«. Journal of Hematology & Oncology. 2: 45. doi:10.1186/1756-8722-2-45. PMC 2775749. PMID 19860903.
Tsang CK, Qi H, Liu LF, Zheng XF (Februar 2007). »Targeting mammalian target of rapamycin (mTOR) for health and diseases«. Drug Discovery Today. 12 (3–4): 112–124. doi:10.1016/j.drudis.2006.12.008. PMID 17275731.
Faivre S, Kroemer G, Raymond E (Avgust 2006). »Current development of mTOR inhibitors as anticancer agents«. Nature Reviews. Drug Discovery. 5 (8): 671–688. doi:10.1038/nrd2062. PMID 16883305. S2CID 27952376.
Vignot S, Faivre S, Aguirre D, Raymond E (april 2005). »mTOR-targeted therapy of cancer with rapamycin derivatives«. Annals of Oncology. 16 (4): 525–537. doi:10.1093/annonc/mdi113. PMID 15728109.{{navedi časopis}}: Vzdrževanje CS1: samodejni prevod datuma (povezava)
Zaytseva YY, Valentino JD, Gulhati P, Evers BM (Junij 2012). »mTOR inhibitors in cancer therapy«. Cancer Letters. 319 (1): 1–7. doi:10.1016/j.canlet.2012.01.005. PMID 22261336.
Vilar E, Perez-Garcia J, Tabernero J (Marec 2011). »Pushing the envelope in the mTOR pathway: the second generation of inhibitors«. Molecular Cancer Therapeutics. 10 (3): 395–403. doi:10.1158/1535-7163.MCT-10-0905. PMC 3413411. PMID 21216931.
Ballou LM, Lin RZ (november 2008). »Rapamycin and mTOR kinase inhibitors«. Journal of Chemical Biology. 1 (1–4): 27–36. doi:10.1007/s12154-008-0003-5. PMC 2698317. PMID 19568796.{{navedi časopis}}: Vzdrževanje CS1: samodejni prevod datuma (povezava)
Brachmann S, Fritsch C, Maira SM, García-Echeverría C (april 2009). »PI3K and mTOR inhibitors: a new generation of targeted anticancer agents«. Current Opinion in Cell Biology. 21 (2): 194–198. doi:10.1016/j.ceb.2008.12.011. PMID 19201591.{{navedi časopis}}: Vzdrževanje CS1: samodejni prevod datuma (povezava)
Zhang YJ, Duan Y, Zheng XF (april 2011). »Targeting the mTOR kinase domain: the second generation of mTOR inhibitors«. Drug Discovery Today. 16 (7–8): 325–331. doi:10.1016/j.drudis.2011.02.008. PMC 3073023. PMID 21333749.{{navedi časopis}}: Vzdrževanje CS1: samodejni prevod datuma (povezava)
Wander SA, Hennessy BT, Slingerland JM (april 2011). »Next-generation mTOR inhibitors in clinical oncology: how pathway complexity informs therapeutic strategy«. The Journal of Clinical Investigation. 121 (4): 1231–1241. doi:10.1172/JCI44145. PMC 3069769. PMID 21490404.{{navedi časopis}}: Vzdrževanje CS1: samodejni prevod datuma (povezava)
Tanneeru K, Guruprasad L (april 2012). »Ligand-based 3-D pharmacophore generation and molecular docking of mTOR kinase inhibitors«. Journal of Molecular Modeling. 18 (4): 1611–1624. doi:10.1007/s00894-011-1184-3. PMID 21805127. S2CID 19207283.{{navedi časopis}}: Vzdrževanje CS1: samodejni prevod datuma (povezava)
Sutherlin DP, Bao L, Berry M, Castanedo G, Chuckowree I, Dotson J, in sod. (november 2011). »Discovery of a potent, selective, and orally available class I phosphatidylinositol 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) kinase inhibitor (GDC-0980) for the treatment of cancer«. Journal of Medicinal Chemistry. 54 (21): 7579–7587. doi:10.1021/jm2009327. PMID 21981714.{{navedi časopis}}: Vzdrževanje CS1: samodejni prevod datuma (povezava)
Simamora P, Alvarez JM, Yalkowsky SH (Februar 2001). »Solubilization of rapamycin«. International Journal of Pharmaceutics. 213 (1–2): 25–29. doi:10.1016/s0378-5173(00)00617-7. PMID 11165091.
Arriola Apelo SI, Neuman JC, Baar EL, Syed FA, Cummings NE, Brar HK, in sod. (Februar 2016). »Alternative rapamycin treatment regimens mitigate the impact of rapamycin on glucose homeostasis and the immune system«. Aging Cell. 15 (1): 28–38. doi:10.1111/acel.12405. PMC 4717280. PMID 26463117.
Wang S, Raybuck A, Shiuan E, Cho SH, Wang Q, Brantley-Sieders DM, in sod. (Avgust 2020). »Selective inhibition of mTORC1 in tumor vessels increases antitumor immunity«. JCI Insight. 5 (15): e139237. doi:10.1172/jci.insight.139237. PMC 7455083. PMID 32759497.
Piccolo R, Nicolino A, Danzi GB (Maj 2014). »The Nobori biolimus-eluting stent: update of available evidence«. Expert Review of Medical Devices. 11 (3): 275–282. doi:10.1586/17434440.2014.894458. PMID 24579987. S2CID 7202232.
Blum M, Cao D, Mehran R (april 2020). »Device profile of the Resolute Onyx Zotarolimus eluting coronary stent system for the treatment of coronary artery disease: overview of its safety and efficacy«. Expert Review of Medical Devices. 17 (4): 257–265. doi:10.1080/17434440.2020.1736037. PMID 32154750. S2CID 212652625.{{navedi časopis}}: Vzdrževanje CS1: samodejni prevod datuma (povezava)
Chen Y, Zhou X (december 2020). »Research progress of mTOR inhibitors«. European Journal of Medicinal Chemistry. 208: 112820. doi:10.1016/j.ejmech.2020.112820. PMID 32966896. S2CID 221887814.{{navedi časopis}}: Vzdrževanje CS1: samodejni prevod datuma (povezava)

europa.eu

ema.europa.eu

»Rapamune«. European Medicines Agency. Arhivirano iz prvotnega spletišča dne 6. aprila 2013. Pridobljeno 25. septembra 2012.
»Torisel«. Evropska agencija za zdravila. Arhivirano iz prvotnega spletišča dne 18. januarja 2013. Pridobljeno 25. septembra 2012.
»Afinitor«. Evropska agencija za zdravila. Arhivirano iz prvotnega spletišča dne 19. decembra 2013. Pridobljeno 25. septembra 2012.
»Votubia«. European Medicines Agency. Arhivirano iz prvotnega spletišča dne 19. oktobra 2012. Pridobljeno 25. septembra 2012.
»Umik vloge za pridobitev dovoljenja za promet z zdravilom Jenzyl (ridaforolimus)« (PDF). Evropska agencija za zdravila. 14. december 2012. Pridobljeno 1. novembra 2023.

fda.gov

accessdata.fda.gov

»Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations«. Food and Drug Administration. Pridobljeno 25. septembra 2012.

fda.gov

»CYPHER Sirolimus-eluting Coronary Stent - P020026«. Urad za hrano in zdravila. Pridobljeno 25. septembra 2012.

nih.gov

pubmed.ncbi.nlm.nih.gov

Pópulo H, Lopes JM, Soares P (2012). »The mTOR signalling pathway in human cancer«. International Journal of Molecular Sciences. 13 (2): 1886–1918. doi:10.3390/ijms13021886. PMC 3291999. PMID 22408430.
Strimpakos AS, Karapanagiotou EM, Saif MW, Syrigos KN (april 2009). »The role of mTOR in the management of solid tumors: an overview«. Cancer Treatment Reviews. 35 (2): 148–159. doi:10.1016/j.ctrv.2008.09.006. PMID 19013721.{{navedi časopis}}: Vzdrževanje CS1: samodejni prevod datuma (povezava)
Yuan R, Kay A, Berg WJ, Lebwohl D (Oktober 2009). »Targeting tumorigenesis: development and use of mTOR inhibitors in cancer therapy«. Journal of Hematology & Oncology. 2: 45. doi:10.1186/1756-8722-2-45. PMC 2775749. PMID 19860903.
Tsang CK, Qi H, Liu LF, Zheng XF (Februar 2007). »Targeting mammalian target of rapamycin (mTOR) for health and diseases«. Drug Discovery Today. 12 (3–4): 112–124. doi:10.1016/j.drudis.2006.12.008. PMID 17275731.
Faivre S, Kroemer G, Raymond E (Avgust 2006). »Current development of mTOR inhibitors as anticancer agents«. Nature Reviews. Drug Discovery. 5 (8): 671–688. doi:10.1038/nrd2062. PMID 16883305. S2CID 27952376.
Vignot S, Faivre S, Aguirre D, Raymond E (april 2005). »mTOR-targeted therapy of cancer with rapamycin derivatives«. Annals of Oncology. 16 (4): 525–537. doi:10.1093/annonc/mdi113. PMID 15728109.{{navedi časopis}}: Vzdrževanje CS1: samodejni prevod datuma (povezava)
Zaytseva YY, Valentino JD, Gulhati P, Evers BM (Junij 2012). »mTOR inhibitors in cancer therapy«. Cancer Letters. 319 (1): 1–7. doi:10.1016/j.canlet.2012.01.005. PMID 22261336.
Vilar E, Perez-Garcia J, Tabernero J (Marec 2011). »Pushing the envelope in the mTOR pathway: the second generation of inhibitors«. Molecular Cancer Therapeutics. 10 (3): 395–403. doi:10.1158/1535-7163.MCT-10-0905. PMC 3413411. PMID 21216931.
Ballou LM, Lin RZ (november 2008). »Rapamycin and mTOR kinase inhibitors«. Journal of Chemical Biology. 1 (1–4): 27–36. doi:10.1007/s12154-008-0003-5. PMC 2698317. PMID 19568796.{{navedi časopis}}: Vzdrževanje CS1: samodejni prevod datuma (povezava)
Brachmann S, Fritsch C, Maira SM, García-Echeverría C (april 2009). »PI3K and mTOR inhibitors: a new generation of targeted anticancer agents«. Current Opinion in Cell Biology. 21 (2): 194–198. doi:10.1016/j.ceb.2008.12.011. PMID 19201591.{{navedi časopis}}: Vzdrževanje CS1: samodejni prevod datuma (povezava)
Zhang YJ, Duan Y, Zheng XF (april 2011). »Targeting the mTOR kinase domain: the second generation of mTOR inhibitors«. Drug Discovery Today. 16 (7–8): 325–331. doi:10.1016/j.drudis.2011.02.008. PMC 3073023. PMID 21333749.{{navedi časopis}}: Vzdrževanje CS1: samodejni prevod datuma (povezava)
Wander SA, Hennessy BT, Slingerland JM (april 2011). »Next-generation mTOR inhibitors in clinical oncology: how pathway complexity informs therapeutic strategy«. The Journal of Clinical Investigation. 121 (4): 1231–1241. doi:10.1172/JCI44145. PMC 3069769. PMID 21490404.{{navedi časopis}}: Vzdrževanje CS1: samodejni prevod datuma (povezava)
Tanneeru K, Guruprasad L (april 2012). »Ligand-based 3-D pharmacophore generation and molecular docking of mTOR kinase inhibitors«. Journal of Molecular Modeling. 18 (4): 1611–1624. doi:10.1007/s00894-011-1184-3. PMID 21805127. S2CID 19207283.{{navedi časopis}}: Vzdrževanje CS1: samodejni prevod datuma (povezava)
Sutherlin DP, Bao L, Berry M, Castanedo G, Chuckowree I, Dotson J, in sod. (november 2011). »Discovery of a potent, selective, and orally available class I phosphatidylinositol 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) kinase inhibitor (GDC-0980) for the treatment of cancer«. Journal of Medicinal Chemistry. 54 (21): 7579–7587. doi:10.1021/jm2009327. PMID 21981714.{{navedi časopis}}: Vzdrževanje CS1: samodejni prevod datuma (povezava)
Simamora P, Alvarez JM, Yalkowsky SH (Februar 2001). »Solubilization of rapamycin«. International Journal of Pharmaceutics. 213 (1–2): 25–29. doi:10.1016/s0378-5173(00)00617-7. PMID 11165091.
Arriola Apelo SI, Neuman JC, Baar EL, Syed FA, Cummings NE, Brar HK, in sod. (Februar 2016). »Alternative rapamycin treatment regimens mitigate the impact of rapamycin on glucose homeostasis and the immune system«. Aging Cell. 15 (1): 28–38. doi:10.1111/acel.12405. PMC 4717280. PMID 26463117.
Wang S, Raybuck A, Shiuan E, Cho SH, Wang Q, Brantley-Sieders DM, in sod. (Avgust 2020). »Selective inhibition of mTORC1 in tumor vessels increases antitumor immunity«. JCI Insight. 5 (15): e139237. doi:10.1172/jci.insight.139237. PMC 7455083. PMID 32759497.
Piccolo R, Nicolino A, Danzi GB (Maj 2014). »The Nobori biolimus-eluting stent: update of available evidence«. Expert Review of Medical Devices. 11 (3): 275–282. doi:10.1586/17434440.2014.894458. PMID 24579987. S2CID 7202232.
Blum M, Cao D, Mehran R (april 2020). »Device profile of the Resolute Onyx Zotarolimus eluting coronary stent system for the treatment of coronary artery disease: overview of its safety and efficacy«. Expert Review of Medical Devices. 17 (4): 257–265. doi:10.1080/17434440.2020.1736037. PMID 32154750. S2CID 212652625.{{navedi časopis}}: Vzdrževanje CS1: samodejni prevod datuma (povezava)
Chen Y, Zhou X (december 2020). »Research progress of mTOR inhibitors«. European Journal of Medicinal Chemistry. 208: 112820. doi:10.1016/j.ejmech.2020.112820. PMID 32966896. S2CID 221887814.{{navedi časopis}}: Vzdrževanje CS1: samodejni prevod datuma (povezava)

ncbi.nlm.nih.gov

Pópulo H, Lopes JM, Soares P (2012). »The mTOR signalling pathway in human cancer«. International Journal of Molecular Sciences. 13 (2): 1886–1918. doi:10.3390/ijms13021886. PMC 3291999. PMID 22408430.
Yuan R, Kay A, Berg WJ, Lebwohl D (Oktober 2009). »Targeting tumorigenesis: development and use of mTOR inhibitors in cancer therapy«. Journal of Hematology & Oncology. 2: 45. doi:10.1186/1756-8722-2-45. PMC 2775749. PMID 19860903.
Vilar E, Perez-Garcia J, Tabernero J (Marec 2011). »Pushing the envelope in the mTOR pathway: the second generation of inhibitors«. Molecular Cancer Therapeutics. 10 (3): 395–403. doi:10.1158/1535-7163.MCT-10-0905. PMC 3413411. PMID 21216931.
Ballou LM, Lin RZ (november 2008). »Rapamycin and mTOR kinase inhibitors«. Journal of Chemical Biology. 1 (1–4): 27–36. doi:10.1007/s12154-008-0003-5. PMC 2698317. PMID 19568796.{{navedi časopis}}: Vzdrževanje CS1: samodejni prevod datuma (povezava)
Zhang YJ, Duan Y, Zheng XF (april 2011). »Targeting the mTOR kinase domain: the second generation of mTOR inhibitors«. Drug Discovery Today. 16 (7–8): 325–331. doi:10.1016/j.drudis.2011.02.008. PMC 3073023. PMID 21333749.{{navedi časopis}}: Vzdrževanje CS1: samodejni prevod datuma (povezava)
Wander SA, Hennessy BT, Slingerland JM (april 2011). »Next-generation mTOR inhibitors in clinical oncology: how pathway complexity informs therapeutic strategy«. The Journal of Clinical Investigation. 121 (4): 1231–1241. doi:10.1172/JCI44145. PMC 3069769. PMID 21490404.{{navedi časopis}}: Vzdrževanje CS1: samodejni prevod datuma (povezava)
Arriola Apelo SI, Neuman JC, Baar EL, Syed FA, Cummings NE, Brar HK, in sod. (Februar 2016). »Alternative rapamycin treatment regimens mitigate the impact of rapamycin on glucose homeostasis and the immune system«. Aging Cell. 15 (1): 28–38. doi:10.1111/acel.12405. PMC 4717280. PMID 26463117.
Wang S, Raybuck A, Shiuan E, Cho SH, Wang Q, Brantley-Sieders DM, in sod. (Avgust 2020). »Selective inhibition of mTORC1 in tumor vessels increases antitumor immunity«. JCI Insight. 5 (15): e139237. doi:10.1172/jci.insight.139237. PMC 7455083. PMID 32759497.

semanticscholar.org

api.semanticscholar.org

Faivre S, Kroemer G, Raymond E (Avgust 2006). »Current development of mTOR inhibitors as anticancer agents«. Nature Reviews. Drug Discovery. 5 (8): 671–688. doi:10.1038/nrd2062. PMID 16883305. S2CID 27952376.
Tanneeru K, Guruprasad L (april 2012). »Ligand-based 3-D pharmacophore generation and molecular docking of mTOR kinase inhibitors«. Journal of Molecular Modeling. 18 (4): 1611–1624. doi:10.1007/s00894-011-1184-3. PMID 21805127. S2CID 19207283.{{navedi časopis}}: Vzdrževanje CS1: samodejni prevod datuma (povezava)
Piccolo R, Nicolino A, Danzi GB (Maj 2014). »The Nobori biolimus-eluting stent: update of available evidence«. Expert Review of Medical Devices. 11 (3): 275–282. doi:10.1586/17434440.2014.894458. PMID 24579987. S2CID 7202232.
Blum M, Cao D, Mehran R (april 2020). »Device profile of the Resolute Onyx Zotarolimus eluting coronary stent system for the treatment of coronary artery disease: overview of its safety and efficacy«. Expert Review of Medical Devices. 17 (4): 257–265. doi:10.1080/17434440.2020.1736037. PMID 32154750. S2CID 212652625.{{navedi časopis}}: Vzdrževanje CS1: samodejni prevod datuma (povezava)
Chen Y, Zhou X (december 2020). »Research progress of mTOR inhibitors«. European Journal of Medicinal Chemistry. 208: 112820. doi:10.1016/j.ejmech.2020.112820. PMID 32966896. S2CID 221887814.{{navedi časopis}}: Vzdrževanje CS1: samodejni prevod datuma (povezava)

termania.net

https://www.termania.net/slovarji/slovenski-medicinski-slovar/5544860/zaviralec?query=Mtor&SearchIn=My, Slovenski medicinski e-slovar, vpogled: 27. 10. 2023.

web.archive.org

»Rapamune«. European Medicines Agency. Arhivirano iz prvotnega spletišča dne 6. aprila 2013. Pridobljeno 25. septembra 2012.
»Torisel«. Evropska agencija za zdravila. Arhivirano iz prvotnega spletišča dne 18. januarja 2013. Pridobljeno 25. septembra 2012.
»FDA approval for Everolimus«. National Cancer Institute. 21. april 2009. Arhivirano iz prvotnega spletišča dne 6. aprila 2015. Pridobljeno 20. septembra 2012.
»Afinitor«. Evropska agencija za zdravila. Arhivirano iz prvotnega spletišča dne 19. decembra 2013. Pridobljeno 25. septembra 2012.
»Votubia«. European Medicines Agency. Arhivirano iz prvotnega spletišča dne 19. oktobra 2012. Pridobljeno 25. septembra 2012.